Olema Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$204.6MTTM through 30 Jun 2026
Free Cash Flow -$164.9MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-38.5%ROE
-41.2%ROA
Balance Sheet Health
Debt / Equity0.01x
Current Ratio10.88x
Net Debt-$502.3Mnet cash position
Cash & Equivalents$48.6M
Quality Metrics
Altman Z-Score6.51
Piotroski F-Score1 / 9
Earnings-Beat Rate50.0%
Multi-Year Trend
Diluted EPS-$2.12TTMFY2025: $-1.87
Dividend
No dividend
Capital Allocation
R&D Spend$190.2M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.